Akut mieloid leukémia (AML): vizsgálatok itt: Németország
45 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleProspective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
- Where
- Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mainz, Mannheim, Muenster, Munich, Oldenburg, Rostock, Ulm
- Életkor
- 18 év to 75 év
- People
- 76
- Run by
- Technische Universität Dresden
See details and how to joinNCT06717958 · EU 2023-509055-14-00 - 1. fázisBefejeződöttSafety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Hanover
- Életkor
- 18 év and over
- People
- 171 worldwide
- Run by
- Kura Oncology, Inc.
See details and how to joinNCT06001788 · EU 2023-510288-37-00 - 2/3. fázisNot yet taking people in NémetországL-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- Where
- Brunswick, Rostock
- Életkor
- 18 év to 80 év
- People
- 312 worldwide
- Run by
- Moleculin Biotech, Inc.
See details and how to joinNCT06788756 · EU 2024-518359-47-00 - 2. fázisNot yet taking people in NémetországRevumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
- Where
- Augsburg, Erlangen, Freiburg im Breisgau, Hamburg, Jena, Mainz, Muenster
- Életkor
- Up to 64 év
- People
- 31 worldwide
- Run by
- Pediatric Research International GmbH
See details and how to join2025-521390-14-00 - 2. fázisBefejeződöttA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Brunswick, Luebeck
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - 1/2. fázisNot yet taking people in NémetországA Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
- Where
- Berlin, Dresden, Heidelberg, Jena, Leipzig, Munich, Ulm
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00 - 2. fázisTaking peoplePhase II study of (early) combination salvage therapy with Venetoclax and intensified Decitabine in Relapsed/Refractory AML
- Where
- Tuebingen
- Életkor
- 18 év and over
- People
- 27
- Run by
- Universitaetsklinikum Tuebingen
See details and how to joinNCT06156579 · EU 2022-502665-15-00 - No phaseTaking peopleAnalysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
- Where
- Freiburg im Breisgau
- Életkor
- 18 év and over
- People
- 20
- Run by
- University of Freiburg
See details and how to joinNCT07627568 - No phaseTaking peopleClinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
- Where
- Aachen, Altenburg, Augsburg, Baden-Baden, Bamberg, Bayreuth, Berlin, Bielefeld, Bochum, Bremen, Chemnitz, Coburg, Cologne, Cottbus, Donauwörth, Dresden, Duisburg, Düren, Düsseldorf, Erfurt, Erlangen, Essen, Frankfurt am Main, Frankfurt (Oder), Fulda, Gütersloh, Halle, Hamm, Heidelberg, Hildesheim, Jena, Kiel, Koblenz, Leipzig, Mannheim, Marburg, Münster, Neubrandenburg, Nuremberg, Riesa, Rostock, Rotenburg (Wümme), Schwäbisch Hall, Schwerin, Siegen, Sindelfingen, Stendal, Stuttgart, Wiesbaden, Winnenden, Wolfsburg, Würzburg, Zwickau
- Életkor
- 18 év and over
- People
- 15 000
- Run by
- Technische Universität Dresden
See details and how to joinNCT03188874 - 1. fázisTaking peopleLong-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
- Where
- Berlin, Dresden, Marburg, Munich, Ulm
- Életkor
- 18 év and over
- People
- 178
- Run by
- AvenCell Therapeutics, Inc.
See details and how to joinNCT07474051 · EU 2025-521717-67-00 - No phaseTaking peopleRegistry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
- Where
- Aschaffenburg, Augsburg, Aurich, Bad Saarow, Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Dortmund, Düsseldorf, Essen, Esslingen am Neckar, Flensburg, Frankfurt, Freiburg im Breisgau, Fulda, Giessen, Goch, Göppingen, Göttingen, Greifswald, Halle, Hamburg, Hamm, Hanau, Hanover, Heilbronn, Herne, Homburg/Saar, Kaiserslautern, Karlsruhe, Kassel, Kiel, Krefeld, Landshut, Lebach, Lemgo, Lübeck, Lüdenscheid, Ludwigshafen, Magdeburg, Mainz, Meschede, Minden, Mühlheim, München, Mutlangen, Neuss, Offenbach, Offenburg, Oldenburg, Passau, Potsdam, Recklinghausen, Regensburg, Rostock, Saarbrücken, Saarlouis, Sande, Stuttgart, Traunstein, Trier, Tübingen, Ulm, Villingen-Schwenningen, Wernigerode, Wuppertal
- Életkor
- 18 év and over
- People
- 50 000 worldwide
- Run by
- University of Ulm
See details and how to joinNCT01252485 - 1/2. fázisFelfüggesztveAB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Chemnitz, Halle (Saale), Leipzig
- Életkor
- 18 év and over
- People
- 78 worldwide
- Run by
- AB Science
See details and how to joinNCT05211570 · EU 2024-516641-39-00 - 1/2. fázisNot yet taking people in NémetországAn Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
- Where
- Munich, Ulm
- Életkor
- 18 év and over
- People
- 143 worldwide
- Run by
- Advesya SAS
See details and how to joinNCT06281847 - 1/2. fázisTaking peopleCombination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
- Where
- Aachen, Augsburg, Chemnitz, Dresden, Duesseldorf, Essen, Frankfurt Am Main, Halle (Saale), Heidelberg, Jena, Kiel, Koblenz, Leipzig, Mannheim, Marburg, Muenster, Munich, Nuremberg, Paderborn, Regensburg, Stuttgart, Wiesbaden, Winnenden
- Életkor
- 18 év to 75 év
- People
- 214
- Run by
- Technische Universität Dresden
See details and how to joinNCT04385290 · EU 2024-514014-13-00 - 1/2. fázisBefejeződöttClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Berlin, Brunswick, Leipzig
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00 - 3. fázisNot yet taking people in NémetországIvosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
- Where
- Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Flensburg, Freiburg im Breisgau, Greifswald, Halle, Hamburg, Hanover, Heilbronn, Karlsruhe, Mainz, Minden, München, Oldenburg, Regensburg, Stuttgart, Tübingen, Ulm
- Életkor
- 18 év and over
- People
- 227 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016 - 2. fázisTaking peopleGilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
- Where
- Aachen, Augsburg, Chemnitz, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Heidelberg, Leipzig, Munich, Münster, Wiesbaden
- Életkor
- 18 év and over
- People
- 60
- Run by
- Technische Universität Dresden
See details and how to joinNCT06696183 · EU 2023-507878-41-00 - 1. fázisNot yet taking people in NémetországGenetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
- Where
- Dresden, Heidelberg
- Életkor
- 18 év and over
- People
- 12
- Run by
- German Cancer Research Center
See details and how to joinNCT05662904 - 1/2. fázisNot yet taking people in NémetországAn adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerability, and clinical activity in patients with relapsed/refractory acute myeloid leukaemia (RESOLVE AML 001)
- Where
- Munich, Ulm
- Életkor
- 18 év and over
- People
- 61 worldwide
- Run by
- CanCell Therapeutics
See details and how to join2023-506865-71-00 - 2. fázisNot yet taking people in NémetországTreatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
- Where
- Essen
- Életkor
- Up to 18 év
- People
- 89 worldwide
- Run by
- Associazione Italiana Ematologia Oncologia Pediatrica
See details and how to joinNCT04793919 · EU 2024-518669-83-00